RNA interference for improving the outcome of islet transplantation

Advanced Drug Delivery Reviews

Volumn 63, Issue 1-2, 2011, Pages 47-68

  Li, Feng ^a   Mahato, Ram I ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Islet transplantation; RNA interference; ShRNA; SiRNA

Indexed keywords

BIO-CONJUGATION; COMPLEX FORMATIONS; CRITICAL DESIGN; GENE SILENCING; IMMUNE REJECTION; INFLAMMATORY CYTOKINES; INFLAMMATORY REACTION; ISLET TRANSPLANTATION; NOVEL STRATEGIES; RNA INTERFERENCE; SHORT HAIRPIN RNA (SHRNA); SHRNA; SIRNA; TYPE 1 DIABETES; VIRAL VECTORS;

CHEMICAL MODIFICATION; GENE EXPRESSION; GENETIC ENGINEERING; RNA;

NUCLEIC ACIDS;

ADENOVIRUS VECTOR; CASPASE 3; CASPASE 8; CD40 ANTIGEN; CD86 ANTIGEN; CELL PENETRATING PEPTIDE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; LENTIVIRUS VECTOR; LIPOFECTAMINE; LIPOPLEX; MACROGOL; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOID DIFFERENTIATION FACTOR 88; PENETRATIN; POLYETHYLENEIMINE; POLYLYSINE; RAPAMYCIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; APOPTOSIS; AUTOIMMUNITY; CELL DEATH; CELL SURVIVAL; COMPLEMENT ACTIVATION; COMPLEX FORMATION; CYTOKINE PRODUCTION; DENDRITIC CELL; DISULFIDE BOND; DNA MODIFICATION; DOWN REGULATION; ENZYME ACTIVATION; GENE SEQUENCE; GENE SILENCING; GRAFT FAILURE; GRAFT REJECTION; HUMAN; HYPOXIA; IMMUNOGENICITY; IMMUNOMODULATION; INFLAMMATION; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY ISCHEMIA; MACROPHAGE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OUTCOME ASSESSMENT; OXYGEN TENSION; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; PROMOTER REGION; REPERFUSION INJURY; REVIEW; RNA INTERFERENCE;

ANIMALS; DRUG DELIVERY SYSTEMS; GENE THERAPY; HUMANS; ISLETS OF LANGERHANS TRANSPLANTATION; RNA INTERFERENCE; RNA, SMALL INTERFERING; TREATMENT OUTCOME;

EID: 79953026793     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2010.11.003     Document Type: Review

References (263)

1. Williams P.W. Notes on diabetes treated with extract and by grafts of sheep's pancreas. Br. Med. J. 1894, 2:1303-1304.
2. Kelly W.D., Lillehei R.C., Merkel F.K., Idezuki Y., Goetz F.C. Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery 1967, 61:827-837.
3. Vardanyan M., Parkin E., Gruessner C., Rodriguez Rilo H.L. Pancreas vs. islet transplantation: a call on the future. Curr. Opin. Organ Transplant. 2010, 15:124-130.
4. Troppmann C. Complications after pancreas transplantation. Curr. Opin. Organ Transplant. 2010, 15:112-118.
5. Shapiro A.M., Lakey J.R., Ryan E.A., Korbutt G.S., Toth E., Warnock G.L., Kneteman N.M., Rajotte R.V. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med. 2000, 343:230-238.
6. Alejandro R., Barton F.B., Hering B.J., Wease S. 2008 update from the Collaborative Islet Transplant Registry. Transplantation 2008, 86:1783-1788.
7. Merani S., Shapiro A.M. Current status of pancreatic islet transplantation. Clin. Sci. (Lond) 2006, 110:611-625.
8. Ryan E.A., Paty B.W., Senior P.A., Bigam D., Alfadhli E., Kneteman N.M., Lakey J.R., Shapiro A.M. Five-year follow-up after clinical islet transplantation. Diabetes 2005, 54:2060-2069.
9. Harlan D.M., Kenyon N.S., Korsgren O., Roep B.O. Current advances and travails in islet transplantation. Diabetes 2009, 58:2175-2184.
10. Narang A.S., Mahato R.I. Biological and biomaterial approaches for improved islet transplantation. Pharmacol. Rev. 2006, 58:194-243.
11. Shapiro A.M., Ricordi C., Hering B.J., Auchincloss H., Lindblad R., Robertson R.P., Secchi A., Brendel M.D., Berney T., Brennan D.C., Cagliero E., Alejandro R., Ryan E.A., DiMercurio B., Morel P., Polonsky K.S., Reems J.A., Bretzel R.G., Bertuzzi F., Froud T., Kandaswamy R., Sutherland D.E., Eisenbarth G., Segal M., Preiksaitis J., Korbutt G.S., Barton F.B., Viviano L., Seyfert-Margolis V., Bluestone J., Lakey J.R. International trial of the Edmonton protocol for islet transplantation. N. Engl. J. Med. 2006, 355:1318-1330.
12. Miszta-Lane H., Mirbolooki M., James Shapiro A.M., Lakey J.R. Stem cell sources for clinical islet transplantation in type 1 diabetes: embryonic and adult stem cells. Med. Hypotheses 2006, 67:909-913.
13. Cheng K., Fraga D., Zhang C., Kotb M., Gaber A.O., Guntaka R.V., Mahato R.I. Adenovirus-based vascular endothelial growth factor gene delivery to human pancreatic islets. Gene Ther. 2004, 11:1105-1116.
14. Mahato R.I., Henry J., Narang A.S., Sabek O., Fraga D., Kotb M., Gaber A.O. Cationic lipid and polymer-based gene delivery to human pancreatic islets. Mol. Ther. 2003, 7:89-100.
15. Narang A.S., Cheng K., Henry J., Zhang C., Sabek O., Fraga D., Kotb M., Gaber A.O., Mahato R.I. Vascular endothelial growth factor gene delivery for revascularization in transplanted human islets. Pharm. Res. 2004, 21:15-25.
16. Panakanti R., Mahato R.I. Bipartite vector encoding hVEGF and hIL-1Ra for ex vivo transduction into human islets. Mol. Pharm. 2009, 6:274-284.
17. Panakanti R., Mahato R.I. Bipartite adenoviral vector encoding hHGF and hIL-1Ra for improved human islet transplantation. Pharm. Res. 2009, 26:587-596.
18. Mahato R.I. Gene expression and silencing for improved islet transplantation. J. Control. Release 2009, 140:262-267.
19. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811.
20. Montgomery M.K., Xu S., Fire A. RNA as a target of double-stranded RNA-mediated genetic interference in Caenorhabditis elegans. Proc. Natl Acad. Sci. USA 1998, 95:15502-15507.
21. Nguyen T., Menocal E.M., Harborth J., Fruehauf J.H. RNAi therapeutics: an update on delivery. Curr. Opin. Mol. Ther. 2008, 10:158-167.
22. de Fougerolles A., Vornlocher H.P., Maraganore J., Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov. 2007, 6:443-453.
23. De Paula D., Bentley M.V., Mahato R.I. Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA 2007, 13:431-456.
24. Chen Y., Cheng G., Mahato R.I. RNAi for treating hepatitis B viral infection. Pharm. Res. 2008, 25:72-86.
25. Scherer L.J., Rossi J.J. Approaches for the sequence-specific knockdown of mRNA. Nat. Biotechnol. 2003, 21:1457-1465.
26. Scherer L., Rossi J.J. RNAi applications in mammalian cells. Biotechniques 2004, 36:557-561.
27. Bertrand J.R., Pottier M., Vekris A., Opolon P., Maksimenko A., Malvy C. Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem. Biophys. Res. Commun. 2002, 296:1000-1004.
28. Miyagishi M., Hayashi M., Taira K. Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets in mammalian cells. Antisense Nucleic Acid Drug Dev. 2003, 13:1-7.
29. van der Windt D.J., Bottino R., Casu A., Campanile N., Cooper D.K. Rapid loss of intraportally transplanted islets: an overview of pathophysiology and preventive strategies. Xenotransplantation 2007, 14:288-297.
30. Bennet W., Groth C.G., Larsson R., Nilsson B., Korsgren O. Isolated human islets trigger an instant blood mediated inflammatory reaction: implications for intraportal islet transplantation as a treatment for patients with type 1 diabetes. Ups. J. Med. Sci. 2000, 105:125-133.
31. Korsgren O., Nilsson B., Berne C., Felldin M., Foss A., Kallen R., Lundgren T., Salmela K., Tibell A., Tufveson G. Current status of clinical islet transplantation. Transplantation 2005, 79:1289-1293.
32. Moberg L., Johansson H., Lukinius A., Berne C., Foss A., Kallen R., Ostraat O., Salmela K., Tibell A., Tufveson G., Elgue G., Nilsson Ekdahl K., Korsgren O., Nilsson B. Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet 2002, 360:2039-2045.
33. Johansson H., Lukinius A., Moberg L., Lundgren T., Berne C., Foss A., Felldin M., Kallen R., Salmela K., Tibell A., Tufveson G., Ekdahl K.N., Elgue G., Korsgren O., Nilsson B. Tissue factor produced by the endocrine cells of the islets of Langerhans is associated with a negative outcome of clinical islet transplantation. Diabetes 2005, 54:1755-1762.
34. Bennet W., Sundberg B., Groth C.G., Brendel M.D., Brandhorst D., Brandhorst H., Bretzel R.G., Elgue G., Larsson R., Nilsson B., Korsgren O. Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation?. Diabetes 1999, 48:1907-1914.
35. Bennet W., Sundberg B., Lundgren T., Tibell A., Groth C.G., Richards A., White D.J., Elgue G., Larsson R., Nilsson B., Korsgren O. Damage to porcine islets of Langerhans after exposure to human blood in vitro, or after intraportal transplantation to cynomologus monkeys: protective effects of sCR1 and heparin. Transplantation 2000, 69:711-719.
36. Moberg L., Korsgren O., Nilsson B. Neutrophilic granulocytes are the predominant cell type infiltrating pancreatic islets in contact with ABO-compatible blood. Clin. Exp. Immunol. 2005, 142:125-131.
37. Contreras J.L., Eckstein C., Smyth C.A., Bilbao G., Vilatoba M., Ringland S.E., Young C., Thompson J.A., Fernandez J.A., Griffin J.H., Eckhoff D.E. Activated protein C preserves functional islet mass after intraportal transplantation: a novel link between endothelial cell activation, thrombosis, inflammation, and islet cell death. Diabetes 2004, 53:2804-2814.
38. Szaba F.M., Smiley S.T. Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood 2002, 99:1053-1059.
39. Kirchhof N., Shibata S., Wijkstrom M., Kulick D.M., Salerno C.T., Clemmings S.M., Heremans Y., Galili U., Sutherland D.E., Dalmasso A.P., Hering B.J. Reversal of diabetes in non-immunosuppressed rhesus macaques by intraportal porcine islet xenografts precedes acute cellular rejection. Xenotransplantation 2004, 11:396-407.
40. Gysemans C., Callewaert H., Overbergh L., Mathieu C. Cytokine signalling in the beta-cell: a dual role for IFNgamma. Biochem. Soc. Trans. 2008, 36:328-333.
41. Nathan C.F. Secretory products of macrophages. J. Clin. Invest. 1987, 79:319-326.
42. Bendtzen K., Mandrup-Poulsen T., Nerup J., Nielsen J.H., Dinarello C.A., Svenson M. Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science 1986, 232:1545-1547.
43. Barshes N.R., Wyllie S., Goss J.A. Inflammation-mediated dysfunction and apoptosis in pancreatic islet transplantation: implications for intrahepatic grafts. J. Leukoc. Biol. 2005, 77:587-597.
44. Arnush M., Heitmeier M.R., Scarim A.L., Marino M.H., Manning P.T., Corbett J.A. IL-1 produced and released endogenously within human islets inhibits beta cell function. J. Clin. Invest. 1998, 102:516-526.
45. Bottino R., Fernandez L.A., Ricordi C., Lehmann R., Tsan M.F., Oliver R., Inverardi L. Transplantation of allogeneic islets of Langerhans in the rat liver: effects of macrophage depletion on graft survival and microenvironment activation. Diabetes 1998, 47:316-323.
46. Montolio M., Biarnes M., Tellez N., Escoriza J., Soler J., Montanya E. Interleukin-1beta and inducible form of nitric oxide synthase expression in early syngeneic islet transplantation. J. Endocrinol. 2007, 192:169-177.
47. Gysemans C.A., Waer M., Valckx D., Laureys J.M., Mihkalsky D., Bouillon R., Mathieu C. Early graft failure of xenogeneic islets in NOD mice is accompanied by high levels of interleukin-1 and low levels of transforming growth factor-beta mRNA in the grafts. Diabetes 2000, 49:1992-1997.
48. Ozasa T., Newton M.R., Dallman M.J., Shimizu S., Gray D.W., Morris P.J. Cytokine gene expression in pancreatic islet grafts in the rat. Transplantation 1997, 64:1152-1159.
49. Thomas H.E., McKenzie M.D., Angstetra E., Campbell P.D., Kay T.W. Beta cell apoptosis in diabetes. Apoptosis 2009, 14:1389-1404.
50. Eizirik D.L., Mandrup-Poulsen T. A choice of death - the signal-transduction of immune-mediated beta-cell apoptosis. Diabetologia 2001, 44:2115-2133.
51. Tau G., Rothman P. Biologic functions of the IFN-gamma receptors. Allergy 1999, 54:1233-1251.
52. Stephanou A., Brar B.K., Scarabelli T.M., Jonassen A.K., Yellon D.M., Marber M.S., Knight R.A., Latchman D.S. Ischemia-induced STAT-1 expression and activation play a critical role in cardiomyocyte apoptosis. J. Biol. Chem. 2000, 275:10002-10008.
53. Chen G., Goeddel D.V. TNF-R1 signaling: a beautiful pathway. Science 2002, 296:1634-1635.
54. Wajant H., Pfizenmaier K., Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 2003, 10:45-65.
55. Rath P.C., Aggarwal B.B. TNF-induced signaling in apoptosis. J. Clin. Immunol. 1999, 19:350-364.
56. Saklatvala J., Dean J., Finch A. Protein kinase cascades in intracellular signalling by interleukin-I and tumour necrosis factor. Biochem. Soc. Symp. 1999, 64:63-77.
57. Kutlu B., Cardozo A.K., Darville M.I., Kruhoffer M., Magnusson N., Orntoft T., Eizirik D.L. Discovery of gene networks regulating cytokine-induced dysfunction and apoptosis in insulin-producing INS-1 cells. Diabetes 2003, 52:2701-2719.
58. Eizirik D.L., Kutlu B., Rasschaert J., Darville M., Cardozo A.K. Use of microarray analysis to unveil transcription factor and gene networks contributing to beta cell dysfunction and apoptosis. Ann. NY Acad. Sci. 2003, 1005:55-74.
59. Cardozo A.K., Heimberg H., Heremans Y., Leeman R., Kutlu B., Kruhoffer M., Orntoft T., Eizirik D.L. A comprehensive analysis of cytokine-induced and nuclear factor-kappa B-dependent genes in primary rat pancreatic beta-cells. J. Biol. Chem. 2001, 276:48879-48886.
60. Ortis F., Cardozo A.K., Crispim D., Storling J., Mandrup-Poulsen T., Eizirik D.L. Cytokine-induced proapoptotic gene expression in insulin-producing cells is related to rapid, sustained, and nonoscillatory nuclear factor-kappaB activation. Mol. Endocrinol. 2006, 20:1867-1879.
61. Corbett J.A., Sweetland M.A., Wang J.L., Lancaster J.R., McDaniel M.L. Nitric oxide mediates cytokine-induced inhibition of insulin secretion by human islets of Langerhans. Proc. Natl Acad. Sci. USA 1993, 90:1731-1735.
62. Emamaullee J.A., Shapiro A.M. Interventional strategies to prevent beta-cell apoptosis in islet transplantation. Diabetes 2006, 55:1907-1914.
63. Hengartner M.O. The biochemistry of apoptosis. Nature 2000, 407:770-776.
64. Green D.R. Apoptotic pathways: paper wraps stone blunts scissors. Cell 2000, 102:1-4.
65. Jansson L. Dissociation between pancreatic islet blood flow and insulin release in the rat. Acta Physiol. Scand. 1985, 124:223-228.
66. Sezai S., Sakurabayashi S., Yamamoto Y., Morita T., Hirano M., Oka H. Hepatic arterial and portal venous oxygen content and extraction in liver cirrhosis. Liver 1993, 13:31-35.
67. Pileggi A., Ricordi C., Alessiani M., Inverardi L. Factors influencing islet of Langerhans graft function and monitoring. Clin. Chim. Acta 2001, 310:3-16.
68. Menger M.D., Yamauchi J., Vollmar B. Revascularization and microcirculation of freely grafted islets of Langerhans. World J. Surg. 2001, 25:509-515.
69. Li X., Chen H., Epstein P.N. Metallothionein protects islets from hypoxia and extends islet graft survival by scavenging most kinds of reactive oxygen species. J. Biol. Chem. 2004, 279:765-771.
70. Sibley R.K., Sutherland D.E., Goetz F., Michael A.F. Recurrent diabetes mellitus in the pancreas iso- and allograft. A light and electron microscopic and immunohistochemical analysis of four cases. Lab. Invest. 1985, 53:132-144.
71. Santamaria P., Nakhleh R.E., Sutherland D.E., Barbosa J.J. Characterization of T lymphocytes infiltrating human pancreas allograft affected by isletitis and recurrent diabetes. Diabetes 1992, 41:53-61.
72. Mora C., Wong F.S., Chang C.H., Flavell R.A. Pancreatic infiltration but not diabetes occurs in the relative absence of MHC class II-restricted CD4 T cells: studies using NOD/CIITA-deficient mice. J. Immunol. 1999, 162:4576-4588.
73. Trapani J.A., Smyth M.J. Functional significance of the perforin/granzyme cell death pathway. Nat. Rev. Immunol. 2002, 2:735-747.
74. Sutton V.R., Davis J.E., Cancilla M., Johnstone R.W., Ruefli A.A., Sedelies K., Browne K.A., Trapani J.A. Initiation of apoptosis by granzyme B requires direct cleavage of bid, but not direct granzyme B-mediated caspase activation. J. Exp. Med. 2000, 192:1403-1414.
75. Estella E., McKenzie M.D., Catterall T., Sutton V.R., Bird P.I., Trapani J.A., Kay T.W., Thomas H.E. Granzyme B-mediated death of pancreatic beta-cells requires the proapoptotic BH3-only molecule bid. Diabetes 2006, 55:2212-2219.
76. Moriwaki M., Itoh N., Miyagawa J., Yamamoto K., Imagawa A., Yamagata K., Iwahashi H., Nakajima H., Namba M., Nagata S., Hanafusa T., Matsuzawa Y. Fas and Fas ligand expression in inflamed islets in pancreas sections of patients with recent-onset Type I diabetes mellitus. Diabetologia 1999, 42:1332-1340.
77. Loweth A.C., Williams G.T., James R.F., Scarpello J.H., Morgan N.G. Human islets of Langerhans express Fas ligand and undergo apoptosis in response to interleukin-1beta and Fas ligation. Diabetes 1998, 47:727-732.
78. Pericin M., Althage A., Freigang S., Hengartner H., Rolland E., Dupraz P., Thorens B., Aebischer P., Zinkernagel R.M. Allogeneic beta-islet cells correct diabetes and resist immune rejection. Proc. Natl Acad. Sci. USA 2002, 99:8203-8206.
79. Campbell P.M., Senior P.A., Salam A., Labranche K., Bigam D.L., Kneteman N.M., Imes S., Halpin A., Ryan E.A., Shapiro A.M. High risk of sensitization after failed islet transplantation. Am. J. Transplant. 2007, 7:2311-2317.
80. Olack B.J., Swanson C.J., Flavin K.S., Phelan D., Brennan D.C., White N.H., Lacy P.E., Scharp D.W., Poindexter N., Mohanakumar T. Sensitization to HLA antigens in islet recipients with failing transplants. Transplant. Proc. 1997, 29:2268-2269.
81. Morel Y., Truneh A., Sweet R.W., Olive D., Costello R.T. The TNF superfamily members LIGHT and CD154 (CD40 ligand) costimulate induction of dendritic cell maturation and elicit specific CTL activity. J. Immunol. 2001, 167:2479-2486.
82. Emamaullee J., Toso C., Merani S., Shapiro A.M. Costimulatory blockade with belatacept in clinical and experimental transplantation - a review. Expert Opin. Biol. Ther. 2009, 9:789-796.
83. Hui H., Khoury N., Zhao X., Balkir L., D'Amico E., Bullotta A., Nguyen E.D., Gambotto A., Perfetti R. Adenovirus-mediated XIAP gene transfer reverses the negative effects of immunosuppressive drugs on insulin secretion and cell viability of isolated human islets. Diabetes 2005, 54:424-433.
84. Bonham C.A., Peng L., Liang X., Chen Z., Wang L., Ma L., Hackstein H., Robbins P.D., Thomson A.W., Fung J.J., Qian S., Lu L. Marked prolongation of cardiac allograft survival by dendritic cells genetically engineered with NF-kappa B oligodeoxyribonucleotide decoys and adenoviral vectors encoding CTLA4-Ig. J. Immunol. 2002, 169:3382-3391.
85. Yoshimura S., Bondeson J., Foxwell B.M., Brennan F.M., Feldmann M. Effective antigen presentation by dendritic cells is NF-kappaB dependent: coordinate regulation of MHC, co-stimulatory molecules and cytokines. Int. Immunol. 2001, 13:675-683.
86. Li M., Zhang X., Zheng X., Lian D., Zhang Z.X., Ge W., Yang J., Vladau C., Suzuki M., Chen D., Zhong R., Garcia B., Jevnikar A.M., Min W.P. Immune modulation and tolerance induction by RelB-silenced dendritic cells through RNA interference. J. Immunol. 2007, 178:5480-5487.
87. Li M., Qian H., Ichim T.E., Ge W.W., Popov I.A., Rycerz K., Neu J., White D., Zhong R., Min W.P. Induction of RNA interference in dendritic cells. Immunol. Res. 2004, 30:215-230.
88. Hill J.A., Ichim T.E., Kusznieruk K.P., Li M., Huang X., Yan X., Zhong R., Cairns E., Bell D.A., Min W.P. Immune modulation by silencing IL-12 production in dendritic cells using small interfering RNA. J. Immunol. 2003, 171:691-696.
89. Liang X., Lu L., Chen Z., Vickers T., Zhang H., Fung J.J., Qian S. Administration of dendritic cells transduced with antisense oligodeoxyribonucleotides targeting CD80 or CD86 prolongs allograft survival. Transplantation 2003, 76:721-729.
90. Suzuki M., Zhang X., Zheng X., Vladau C., Li M., Chen D., Min W. Immune modulation through silencing CD80 and CD86 in dendritic cells using siRNA. J. Immunol. 2007, 178:84.
91. Xiang J., Gu X., Qian S., Chen Z. Graded function of CD80 and CD86 in initiation of T-cell immune response and cardiac allograft survival. Transpl. Int. 2008, 21:163-168.
92. Karimi M.H., Ebadi P., Pourfathollah A.A., Soheili Z.S., Samiee S., Ataee Z., Tabei S.Z., Moazzeni S.M. Immune modulation through RNA interference-mediated silencing of CD40 in dendritic cells. Cell. Immunol. 2009, 259:74-81.
93. Zheng X., Vladau C., Zhang X., Suzuki M., Ichim T.E., Zhang Z.X., Li M., Carrier E., Garcia B., Jevnikar A.M., Min W.P. A novel in vivo siRNA delivery system specifically targeting dendritic cells and silencing CD40 genes for immunomodulation. Blood 2009, 113:2646-2654.
94. Zhu C., Xu H., Zhang G., Lu C., Ji M., Wu W. Myeloid differentiation factor 88-silenced bone marrow-derived dendritic cells exhibit enhanced tolerogenicity in intestinal transplantation in rats. Transplant. Proc. 2008, 40:1625-1628.
95. Zhu C., Xu H., Zhang J., Wang K., Zhu P. Donor bone-marrow suppressor of cytokine signaling-1-silenced dendritic cells prolong rat intestinal allograft survival. Transplant. Proc. 2008, 40:3707-3710.
96. Bouwman L.H., Ling Z., Duinkerken G., Pipeleers D.G., Roep B.O. HLA incompatibility and immunogenicity of human pancreatic islet preparations cocultured with blood cells of healthy donors. Hum. Immunol. 2005, 66:494-500.
97. Haga K., Lemp N.A., Logg C.R., Nagashima J., Faure-Kumar E., Gomez G.G., Kruse C.A., Mendez R., Stripecke R., Kasahara N., Cicciarelli J.C. Permanent, lowered HLA class I expression using lentivirus vectors with shRNA constructs: averting cytotoxicity by alloreactive T lymphocytes. Transplant. Proc. 2006, 38:3184-3188.
98. Hacke K., Falahati R., Flebbe-Rehwaldt L., Kasahara N., Gaensler K.M. Suppression of HLA expression by lentivirus-mediated gene transfer of siRNA cassettes and in vivo chemoselection to enhance hematopoietic stem cell transplantation. Immunol. Res. 2009, 44:112-126.
99. Figueiredo C., Seltsam A., Holtkamp U., Blasczyk R. Stable knock down of non-acceptable HLA mismatches in solid organ transplantation. Hum. Immunol. 2004, 65:S7.
100. Figueiredo C., Seltsam A., Blasczyk R. Class-, gene-, and group-specific HLA silencing by lentiviral shRNA delivery. J. Mol. Med. 2006, 84:425-437.
101. Marzorati S., Pileggi A., Ricordi C. Allogeneic islet transplantation. Expert Opin. Biol. Ther. 2007, 7:1627-1645.
102. Zheng X., Zhang X., Sun H., Feng B., Li M., Chen G., Vladau C., Chen D., Suzuki M., Min L., Liu W., Zhong R., Garcia B., Jevnikar A., Min W.P. Protection of renal ischemia injury using combination gene silencing of complement 3 and caspase 3 genes. Transplantation 2006, 82:1781-1786.
103. Zhang X., Zheng X., Sun H., Feng B., Chen G., Vladau C., Li M., Chen D., Suzuki M., Min L., Liu W., Garcia B., Zhong R., Min W.P. Prevention of renal ischemic injury by silencing the expression of renal caspase 3 and caspase 8. Transplantation 2006, 82:1728-1732.
104. Contreras J.L., Vilatoba M., Eckstein C., Bilbao G., Anthony Thompson J., Eckhoff D.E. Caspase-8 and caspase-3 small interfering RNA decreases ischemia/reperfusion injury to the liver in mice. Surgery 2004, 136:390-400.
105. Cheng G., Zhu L., Mahato R.I. Caspase-3 gene silencing for inhibiting apoptosis in insulinoma cells and human islets. Mol. Pharm. 2008, 5:1093-1102.
106. Burkhardt B.R., Lyle R., Qian K., Arnold A.S., Cheng H., Atkinson M.A., Zhang Y.C. Efficient delivery of siRNA into cytokine-stimulated insulinoma cells silences Fas expression and inhibits Fas-mediated apoptosis. FEBS Lett. 2006, 580:553-560.
107. Wang J., Li W., Min J., Ou Q., Chen J. Fas siRNA reduces apoptotic cell death of allogeneic-transplanted hepatocytes in mouse spleen. Transplant. Proc. 2003, 35:1594-1595.
108. Li X., Zhang J.F., Lu M.Q., Yang Y., Xu C., Li H., Wang G.S., Cai C.J., Chen G.H. Alleviation of ischemia-reperfusion injury in rat liver transplantation by induction of small interference RNA targeting Fas. Langenbecks Arch. Surg. 2007, 392:345-351.
109. Zheng X., Lian D., Wong A., Bygrave M., Ichim T.E., Khoshniat M., Zhang X., Sun H., De Zordo T., Lacefield J.C., Garcia B., Jevnikar A.M., Min W.P. Novel small interfering RNA-containing solution protecting donor organs in heart transplantation. Circulation 2009, 120:1099-1107. (1091 p following 1107).
110. Zheng X., Zhang X., Feng B., Sun H., Suzuki M., Ichim T., Kubo N., Wong A., Min L.R., Budohn M.E., Garcia B., Jevnikar A.M., Min W.P. Gene silencing of complement C5a receptor using siRNA for preventing ischemia/reperfusion injury. Am. J. Pathol. 2008, 173:973-980.
111. McCabe C., O'Brien T. Beta cell cytoprotection using lentiviral vector-based iNOS-specific shRNA delivery. Biochem. Biophys. Res. Commun. 2007, 357:75-80.
112. McCabe C., O'Brien T. The rational design of beta cell cytoprotective gene transfer strategies: targeting deleterious iNOS expression. Mol. Biotechnol. 2007, 37:38-47.
113. Li F., Mahato R.I. iNOS gene silencing prevents inflammatory cytokine-induced beta-cell apoptosis. Mol. Pharm. 2008, 5:407-417.
114. De Paula D., Bentley M.V., Mahato R.I. Effect of iNOS and NF-kappaB gene silencing on beta-cell survival and function. J. Drug Target. 2007, 15:358-369.
115. Li F., Mahato R.I. Bipartite vectors for co-expression of a growth factor cDNA and short hairpin RNA against an apoptotic gene. J. Gene Med. 2009, 11:764-771.
116. Pinkenburg O., Platz J., Beisswenger C., Vogelmeier C., Bals R. Inhibition of NF-kappaB mediated inflammation by siRNA expressed by recombinant adeno-associated virus. J. Virol. Meth. 2004, 120:119-122.
117. Feng B., Chen G., Zheng X., Sun H., Zhang X., Zhang Z.X., Xiang Y., Ichim T.E., Garcia B., Luke P., Jevnikar A.M., Min W.P. Small interfering RNA targeting RelB protects against renal ischemia-reperfusion injury. Transplantation 2009, 87:1283-1289.
118. Lee Y.S., Nakahara K., Pham J.W., Kim K., He Z., Sontheimer E.J., Carthew R.W. Distinct roles for Drosophila Dicer-1 and Dicer-2 in the siRNA/miRNA silencing pathways. Cell 2004, 117:69-81.
119. Wang L., Mu F.Y. A web-based design center for vector-based siRNA and siRNA cassette. Bioinformatics 2004, 20:1818-1820.
120. Naito Y., Yamada T., Ui-Tei K., Morishita S., Saigo K. siDirect: highly effective, target-specific siRNA design software for mammalian RNA interference. Nucleic Acids Res. 2004, 32:W124-W129.
121. Yuan B., Latek R., Hossbach M., Tuschl T., Lewitter F. siRNA selection server: an automated siRNA oligonucleotide prediction server. Nucleic Acids Res. 2004, 32:W130-W134.
122. Henschel A., Buchholz F., Habermann B. DEQOR: a web-based tool for the design and quality control of siRNAs. Nucleic Acids Res. 2004, 32:W113-W120.
123. Li L., Lin X., Khvorova A., Fesik S.W., Shen Y. Defining the optimal parameters for hairpin-based knockdown constructs. RNA 2007, 13:1765-1774.
124. Harborth J., Elbashir S.M., Vandenburgh K., Manninga H., Scaringe S.A., Weber K., Tuschl T. Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev. 2003, 13:83-105.
125. Jackson A.L., Burchard J., Schelter J., Chau B.N., Cleary M., Lim L., Linsley P.S. Widespread siRNA 'off-target' transcript silencing mediated by seed region sequence complementarity. RNA 2006, 12:1179-1187.
126. Judge A.D., Sood V., Shaw J.R., Fang D., McClintock K., MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 2005, 23:457-462.
127. Taxman D.J., Livingstone L.R., Zhang J., Conti B.J., Iocca H.A., Williams K.L., Lich J.D., Ting J.P., Reed W. Criteria for effective design, construction, and gene knockdown by shRNA vectors. BMC Biotechnol. 2006, 6:7.
128. Hernandez N. Small nuclear RNA genes: a model system to study fundamental mechanisms of transcription. J. Biol. Chem. 2001, 276:26733-26736.
129. Song J., Pang S., Lu Y., Chiu R. Poly(U) and polyadenylation termination signals are interchangeable for terminating the expression of shRNA from a pol II promoter. Biochem. Biophys. Res. Commun. 2004, 323:573-578.
130. Zeng Y., Wagner E.J., Cullen B.R. Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol. Cell 2002, 9:1327-1333.
131. Denti M.A., Rosa A., Sthandier O., De Angelis F.G., Bozzoni I. A new vector, based on the PolII promoter of the U1 snRNA gene, for the expression of siRNAs in mammalian cells. Mol. Ther. 2004, 10:191-199.
132. Huang M., Jia F.J., Yan Y.C., Guo L.H., Li Y.P. Transactivated minimal E1b promoter is capable of driving the expression of short hairpin RNA. J. Virol. Meth. 2006, 134:48-54.
133. Xia X.G., Zhou H., Ding H., Affar el B., Shi Y., Xu Z. An enhanced U6 promoter for synthesis of short hairpin RNA. Nucleic Acids Res. 2003, 31:e100.
134. Ong S.T., Li F., Du J., Tan Y.W., Wang S. Hybrid cytomegalovirus enhancer-h1 promoter-based plasmid and baculovirus vectors mediate effective RNA interference. Hum. Gene Ther. 2005, 16:1404-1412.
135. Hassani Z., Francois J.C., Alfama G., Dubois G.M., Paris M., Giovannangeli C., Demeneix B.A. A hybrid CMV-H1 construct improves efficiency of PEI-delivered shRNA in the mouse brain. Nucleic Acids Res. 2007, 35:e65.
136. Brenz Verca M.S., Weber P., Mayer C., Graf C., Refojo D., Kuhn R., Grummt I., Lutz B. Development of a species-specific RNA polymerase I-based shRNA expression vector. Nucleic Acids Res. 2007, 35:e10.
137. Lee S.K., Kumar P. Conditional RNAi: towards a silent gene therapy. Adv. Drug Deliv. Rev. 2009, 61:650-664.
138. Czauderna F., Santel A., Hinz M., Fechtner M., Durieux B., Fisch G., Leenders F., Arnold W., Giese K., Klippel A., Kaufmann J. Inducible shRNA expression for application in a prostate cancer mouse model. Nucleic Acids Res. 2003, 31:e127.
139. van de Wetering M., Oving I., Muncan V., Pon Fong M.T., Brantjes H., van Leenen D., Holstege F.C., Brummelkamp T.R., Agami R., Clevers H. Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector. EMBO Rep. 2003, 4:609-615.
140. Higuchi M., Tsutsumi R., Higashi H., Hatakeyama M. Conditional gene silencing utilizing the lac repressor reveals a role of SHP-2 in cagA-positive Helicobacter pylori pathogenicity. Cancer Sci. 2004, 95:442-447.
141. Heinonen J.E., Mohamed A.J., Nore B.F., Smith C.I. Inducible H1 promoter-driven lentiviral siRNA expression by Stuffer reporter deletion. Oligonucleotides 2005, 15:139-144.
142. Kim H.A., Lee B.W., Kang D., Kim J.H., Ihm S.H., Lee M. Delivery of hypoxia-inducible VEGF gene to rat islets using polyethylenimine. J. Drug Target. 2009, 17:1-9.
143. Lee B.W., Chae H.Y., Tuyen T.T., Kang D., Kim H.A., Lee M., Ihm S.H. A comparison of non-viral vectors for gene delivery to pancreatic beta-cells: delivering a hypoxia-inducible vascular endothelial growth factor gene to rat islets. Int. J. Mol. Med. 2009, 23:757-762.
144. Chai R., Chen S., Ding J., Grayburn P.A. Efficient, glucose responsive and islet-specific transgene expression by a modified rat insulin promoter. Gene Ther. 2009, 16:1202-1209.
145. Iwakura H., Hosoda K., Son C., Fujikura J., Tomita T., Noguchi M., Ariyasu H., Takaya K., Masuzaki H., Ogawa Y., Hayashi T., Inoue G., Akamizu T., Hosoda H., Kojima M., Itoh H., Toyokuni S., Kangawa K., Nakao K. Analysis of rat insulin II promoter-ghrelin transgenic mice and rat glucagon promoter-ghrelin transgenic mice. J. Biol. Chem. 2005, 280:15247-15256.
146. Grzech M., Dahlhoff M., Herbach N., Habermann F.A., Renner-Muller I., Wanke R., Flaswinkel H., Wolf E., Schneider M.R. Specific transgene expression in mouse pancreatic beta-cells under the control of the porcine insulin promoter. Mol. Cell. Endocrinol. 2010, 315:219-224.
147. Avnit-Sagi T., Kantorovich L., Kredo-Russo S., Hornstein E., Walker M.D. The promoter of the pri-miR-375 gene directs expression selectively to the endocrine pancreas. PLoS ONE 2009, 4:e5033.
148. Siolas D., Lerner C., Burchard J., Ge W., Linsley P.S., Paddison P.J., Hannon G.J., Cleary M.A. Synthetic shRNAs as potent RNAi triggers. Nat. Biotechnol. 2005, 23:227-231.
149. Jeanson-Leh L., Blondeau J., Galy A. Optimization of short hairpin RNA for lentiviral-mediated RNAi against WAS. Biochem. Biophys. Res. Commun. 2007, 362:498-503.
150. Boden D., Pusch O., Silbermann R., Lee F., Tucker L., Ramratnam B. Enhanced gene silencing of HIV-1 specific siRNA using microRNA designed hairpins. Nucleic Acids Res. 2004, 32:1154-1158.
151. Silva J.M., Li M.Z., Chang K., Ge W., Golding M.C., Rickles R.J., Siolas D., Hu G., Paddison P.J., Schlabach M.R., Sheth N., Bradshaw J., Burchard J., Kulkarni A., Cavet G., Sachidanandam R., McCombie W.R., Cleary M.A., Elledge S.J., Hannon G.J. Second-generation shRNA libraries covering the mouse and human genomes. Nat. Genet. 2005, 37:1281-1288.
152. Stegmeier F., Hu G., Rickles R.J., Hannon G.J., Elledge S.J. A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc. Natl Acad. Sci. USA 2005, 102:13212-13217.
153. Boudreau R.L., Monteys A.M., Davidson B.L. Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs. RNA 2008, 14:1834-1844.
154. Boudreau R.L., Martins I., Davidson B.L. Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. Mol. Ther. 2009, 17:169-175.
155. Nielsen T.T., Marion I., Hasholt L., Lundberg C. Neuron-specific RNA interference using lentiviral vectors. J. Gene Med. 2009, 11:559-569.
156. Chung K.H., Hart C.C., Al-Bassam S., Avery A., Taylor J., Patel P.D., Vojtek A.B., Turner D.L. Polycistronic RNA polymerase II expression vectors for RNA interference based on BIC/miR-155. Nucleic Acids Res. 2006, 34:e53.
157. Aagaard L.A., Zhang J., von Eije K.J., Li H., Saetrom P., Amarzguioui M., Rossi J.J. Engineering and optimization of the miR-106b cluster for ectopic expression of multiplexed anti-HIV RNAs. Gene Ther. 2008, 15:1536-1549.
158. Scherer L.J., Frank R., Rossi J.J. Optimization and characterization of tRNA-shRNA expression constructs. Nucleic Acids Res. 2007, 35:2620-2628.
159. Kawasaki H., Taira K. Short hairpin type of dsRNAs that are controlled by tRNA(Val) promoter significantly induce RNAi-mediated gene silencing in the cytoplasm of human cells. Nucleic Acids Res. 2003, 31:700-707.
160. Boden D., Pusch O., Lee F., Tucker L., Shank P.R., Ramratnam B. Promoter choice affects the potency of HIV-1 specific RNA interference. Nucleic Acids Res. 2003, 31:5033-5038.
161. Kuwabara T., Warashina M., Sano M., Tang H., Wong-Staal F., Munekata E., Taira K. Recognition of engineered tRNAs with an extended 3' end by Exportin-t (Xpo-t) and transport of tRNA-attached ribozymes to the cytoplasm in somatic cells. Biomacromolecules 2001, 2:1229-1242.
162. Zheng L., Liu J., Batalov S., Zhou D., Orth A., Ding S., Schultz P.G. An approach to genomewide screens of expressed small interfering RNAs in mammalian cells. Proc. Natl Acad. Sci. USA 2004, 101:135-140.
163. Jackson A.L., Bartz S.R., Schelter J., Kobayashi S.V., Burchard J., Mao M., Li B., Cavet G., Linsley P.S. Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 2003, 21:635-637.
164. Jackson A.L., Linsley P.S. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat. Rev. Drug Discov. 2010, 9:57-67.
165. Rao D.D., Vorhies J.S., Senzer N., Nemunaitis J. siRNA vs. shRNA: similarities and differences. Adv. Drug Deliv. Rev. 2009, 61:746-759.
166. Jackson A.L., Burchard J., Leake D., Reynolds A., Schelter J., Guo J., Johnson J.M., Lim L., Karpilow J., Nichols K., Marshall W., Khvorova A., Linsley P.S. Position-specific chemical modification of siRNAs reduces 'off-target' transcript silencing. RNA 2006, 12:1197-1205.
167. Lin X., Ruan X., Anderson M.G., McDowell J.A., Kroeger P.E., Fesik S.W., Shen Y. siRNA-mediated off-target gene silencing triggered by a 7nt complementation. Nucleic Acids Res. 2005, 33:4527-4535.
168. Qiu S., Adema C.M., Lane T. A computational study of off-target effects of RNA interference. Nucleic Acids Res. 2005, 33:1834-1847.
169. Du Q., Thonberg H., Wang J., Wahlestedt C., Liang Z. A systematic analysis of the silencing effects of an active siRNA at all single-nucleotide mismatched target sites. Nucleic Acids Res. 2005, 33:1671-1677.
170. Bramsen J.B., Laursen M.B., Damgaard C.K., Lena S.W., Babu B.R., Wengel J., Kjems J. Improved silencing properties using small internally segmented interfering RNAs. Nucleic Acids Res. 2007, 35:5886-5897.
171. Ui-Tei K., Naito Y., Zenno S., Nishi K., Yamato K., Takahashi F., Juni A., Saigo K. Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect. Nucleic Acids Res. 2008, 36:2136-2151.
172. Marques J.T., Devosse T., Wang D., Zamanian-Daryoush M., Serbinowski P., Hartmann R., Fujita T., Behlke M.A., Williams B.R. A structural basis for discriminating between self and nonself double-stranded RNAs in mammalian cells. Nat. Biotechnol. 2006, 24:559-565.
173. Kim D.H., Behlke M.A., Rose S.D., Chang M.S., Choi S., Rossi J.J. Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat. Biotechnol. 2005, 23:222-226.
174. Marques J.T., Williams B.R. Activation of the mammalian immune system by siRNAs. Nat. Biotechnol. 2005, 23:1399-1405.
175. Saunders L.R., Barber G.N. The dsRNA binding protein family: critical roles, diverse cellular functions. FASEB J. 2003, 17:961-983.
176. Hornung V., Guenthner-Biller M., Bourquin C., Ablasser A., Schlee M., Uematsu S., Noronha A., Manoharan M., Akira S., de Fougerolles A., Endres S., Hartmann G. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 2005, 11:263-270.
177. Sledz C.A., Holko M., de Veer M.J., Silverman R.H., Williams B.R. Activation of the interferon system by short-interfering RNAs. Nat. Cell Biol. 2003, 5:834-839.
178. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K., Akira S. A toll-like receptor recognizes bacterial DNA. Nature 2000, 408:740-745.
179. de Wolf H.K., Johansson N., Thong A.T., Snel C.J., Mastrobattista E., Hennink W.E., Storm G. Plasmid CpG depletion improves degree and duration of tumor gene expression after intravenous administration of polyplexes. Pharm. Res. 2008, 25:1654-1662.
180. Grimm D., Kay M.A. Therapeutic application of RNAi: is mRNA targeting finally ready for prime time?. J. Clin. Invest. 2007, 117:3633-3641.
181. Cheng K., Yang N., Mahato R.I. TGF-beta1 gene silencing for treating liver fibrosis. Mol. Pharm. 2009, 6:772-779.
182. Chen Y., Mahato R.I. siRNA pool targeting different sites of human hepatitis B surface antigen efficiently inhibits HBV infection. J. Drug Target. 2008, 16:140-148.
183. Grimm D., Kay M.A. Combinatorial RNAi: a winning strategy for the race against evolving targets?. Mol. Ther. 2007, 15:878-888.
184. Gonzalez S., Castanotto D., Li H., Olivares S., Jensen M.C., Forman S.J., Rossi J.J., Cooper L.J. Amplification of RNAi-targeting HLA mRNAs. Mol. Ther. 2005, 11:811-818.
185. Zhou H., Xia X.G., Xu Z. An RNA polymerase II construct synthesizes short-hairpin RNA with a quantitative indicator and mediates highly efficient RNAi. Nucleic Acids Res. 2005, 33:e62.
186. Xia X.G., Zhou H., Samper E., Melov S., Xu Z. Pol II-expressed shRNA knocks down Sod2 gene expression and causes phenotypes of the gene knockout in mice. PLoS Genet. 2006, 2:e10.
187. Sun D., Melegari M., Sridhar S., Rogler C.E., Zhu L. Multi-miRNA hairpin method that improves gene knockdown efficiency and provides linked multi-gene knockdown. Biotechniques 2006, 41:59-63.
188. Weinberg M.S., Ely A., Barichievy S., Crowther C., Mufamadi S., Carmona S., Arbuthnot P. Specific inhibition of HBV replication in vitro and in vivo with expressed long hairpin RNA. Mol. Ther. 2007, 15:534-541.
189. Saayman S., Barichievy S., Capovilla A., Morris K.V., Arbuthnot P., Weinberg M.S. The efficacy of generating three independent anti-HIV-1 siRNAs from a single U6 RNA Pol III-expressed long hairpin RNA. PLoS ONE 2008, 3:e2602.
190. Liu Y.P., Haasnoot J., Berkhout B. Design of extended short hairpin RNAs for HIV-1 inhibition. Nucleic Acids Res. 2007, 35:5683-5693.
191. Liu Y.P., von Eije K.J., Schopman N.C., Westerink J.T., ter Brake O., Haasnoot J., Berkhout B. Combinatorial RNAi against HIV-1 using extended short hairpin RNAs. Mol. Ther. 2009, 17:1712-1723.
192. Yu J.Y., Taylor J., DeRuiter S.L., Vojtek A.B., Turner D.L. Simultaneous inhibition of GSK3alpha and GSK3beta using hairpin siRNA expression vectors. Mol. Ther. 2003, 7:228-236.
193. Jazag A., Kanai F., Ijichi H., Tateishi K., Ikenoue T., Tanaka Y., Ohta M., Imamura J., Guleng B., Asaoka Y., Kawabe T., Miyagishi M., Taira K., Omata M. Single small-interfering RNA expression vector for silencing multiple transforming growth factor-beta pathway components. Nucleic Acids Res. 2005, 33:e131.
194. Shin K.J., Wall E.A., Zavzavadjian J.R., Santat L.A., Liu J., Hwang J.I., Rebres R., Roach T., Seaman W., Simon M.I., Fraser I.D. A single lentiviral vector platform for microRNA-based conditional RNA interference and coordinated transgene expression. Proc. Natl Acad. Sci. USA 2006, 103:13759-13764.
195. Samakoglu S., Lisowski L., Budak-Alpdogan T., Usachenko Y., Acuto S., Di Marzo R., Maggio A., Zhu P., Tisdale J.F., Riviere I., Sadelain M. A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference. Nat. Biotechnol. 2006, 24:89-94.
196. Qiu L., Wang H., Xia X., Zhou H., Xu Z. A construct with fluorescent indicators for conditional expression of miRNA. BMC Biotechnol. 2008, 8:77.
197. Juliano R., Bauman J., Kang H., Ming X. Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol. Pharm. 2009, 6:686-695.
198. Lewis D.L., Wolff J.A. Systemic siRNA delivery via hydrodynamic intravascular injection. Adv. Drug Deliv. Rev. 2007, 59:115-123.
199. Bradley S.P., Kowalik T.F., Rastellini C., da Costa M.A., Bloomenthal A.B., Cicalese L., Basadonna G.P., Uknis M.E. Successful incorporation of short-interfering RNA into islet cells by in situ perfusion. Transplant. Proc. 2005, 37:233-236.
200. Lefebvre B., Vandewalle B., Longue J., Moerman E., Lukowiak B., Gmyr V., Maedler K., Kerr-conte J., Pattou F. Efficient gene delivery and silencing of mouse and human pancreatic islets. BMC Biotechnol 2010, 10:28.
201. Behlke M.A. Chemical modification of siRNAs for in vivo use. Oligonucleotides 2008, 18:305-319.
202. Corey D.R. Chemical modification: the key to clinical application of RNA interference?. J. Clin. Invest. 2007, 117:3615-3622.
203. Morrissey D.V., Blanchard K., Shaw L., Jensen K., Lockridge J.A., Dickinson B., McSwiggen J.A., Vargeese C., Bowman K., Shaffer C.S., Polisky B.A., Zinnen S. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology 2005, 41:1349-1356.
204. Morrissey D.V., Lockridge J.A., Shaw L., Blanchard K., Jensen K., Breen W., Hartsough K., Machemer L., Radka S., Jadhav V., Vaish N., Zinnen S., Vargeese C., Bowman K., Shaffer C.S., Jeffs L.B., Judge A., MacLachlan I., Polisky B. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 2005, 23:1002-1007.
205. Choung S., Kim Y.J., Kim S., Park H.O., Choi Y.C. Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochem. Biophys. Res. Commun. 2006, 342:919-927.
206. Czauderna F., Fechtner M., Dames S., Aygun H., Klippel A., Pronk G.J., Giese K., Kaufmann J. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. 2003, 31:2705-2716.
207. Santel A., Aleku M., Keil O., Endruschat J., Esche V., Durieux B., Loffler K., Fechtner M., Rohl T., Fisch G., Dames S., Arnold W., Giese K., Klippel A., Kaufmann J. RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy. Gene Ther. 2006, 13:1360-1370.
208. Turner J.J., Jones S.W., Moschos S.A., Lindsay M.A., Gait M.J. MALDI-TOF mass spectral analysis of siRNA degradation in serum confirms an RNAse A-like activity. Mol. Biosyst. 2007, 3:43-50.
209. Judge A.D., Bola G., Lee A.C., MacLachlan I. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol. Ther. 2006, 13:494-505.
210. Robbins M., Judge A., Liang L., McClintock K., Yaworski E., MacLachlan I. 2'-O-methyl-modified RNAs act as TLR7 antagonists. Mol. Ther. 2007, 15:1663-1669.
211. Felgner P.L., Gadek T.R., Holm M., Roman R., Chan H.W., Wenz M., Northrop J.P., Ringold G.M., Danielsen M. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl Acad. Sci. USA 1987, 84:7413-7417.
212. Narang A.S., Thoma L., Miller D.D., Mahato R.I. Cationic lipids with increased DNA binding affinity for nonviral gene transfer in dividing and nondividing cells. Bioconjug. Chem. 2005, 16:156-168.
213. Takahashi Y., Nishikawa M., Takakura Y. Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAi-based gene therapy. Adv. Drug Deliv. Rev. 2009, 61:760-766.
214. Breunig M., Lungwitz U., Liebl R., Goepferich A. Breaking up the correlation between efficacy and toxicity for nonviral gene delivery. Proc. Natl Acad. Sci. USA 2007, 104:14454-14459.
215. Lee Y., Mo H., Koo H., Park J.Y., Cho M.Y., Jin G.W., Park J.S. Visualization of the degradation of a disulfide polymer, linear poly(ethylenimine sulfide), for gene delivery. Bioconjug. Chem. 2007, 18:13-18.
216. Hoon Jeong J., Christensen L.V., Yockman J.W., Zhong Z., Engbersen J.F., Jong Kim W., Feijen J., Wan Kim S. Reducible poly(amido ethylenimine) directed to enhance RNA interference. Biomaterials 2007, 28:1912-1917.
217. Breunig M., Hozsa C., Lungwitz U., Watanabe K., Umeda I., Kato H., Goepferich A. Mechanistic investigation of poly(ethylene imine)-based siRNA delivery: disulfide bonds boost intracellular release of the cargo. J. Control. Release 2008, 130:57-63.
218. Stevenson M., Ramos-Perez V., Singh S., Soliman M., Preece J.A., Briggs S.S., Read M.L., Seymour L.W. Delivery of siRNA mediated by histidine-containing reducible polycations. J. Control. Release 2008, 130:46-56.
219. Wang X.L., Jensen R., Lu Z.R. A novel environment-sensitive biodegradable polydisulfide with protonatable pendants for nucleic acid delivery. J. Control. Release 2007, 120:250-258.
220. Ou M., Wang X.L., Xu R., Chang C.W., Bull D.A., Kim S.W. Novel biodegradable poly(disulfide amine)s for gene delivery with high efficiency and low cytotoxicity. Bioconjug. Chem. 2008, 19:626-633.
221. Green J.J., Shi J., Chiu E., Leshchiner E.S., Langer R., Anderson D.G. Biodegradable polymeric vectors for gene delivery to human endothelial cells. Bioconjug. Chem. 2006, 17:1162-1169.
222. Jere D., Xu C.X., Arote R., Yun C.H., Cho M.H., Cho C.S. Poly(beta-amino ester) as a carrier for si/shRNA delivery in lung cancer cells. Biomaterials 2008, 29:2535-2547.
223. Vandenbroucke R.E., De Geest B.G., Bonne S., Vinken M., Van Haecke T., Heimberg H., Wagner E., Rogiers V., De Smedt S.C., Demeester J., Sanders N.N. Prolonged gene silencing in hepatoma cells and primary hepatocytes after small interfering RNA delivery with biodegradable poly(beta-amino esters). J. Gene Med. 2008, 10:783-794.
224. Tseng S.J., Tang S.C. Development of poly(amino ester glycol urethane)/siRNA polyplexes for gene silencing. Bioconjug. Chem. 2007, 18:1383-1390.
225. Zhao Z., Wang J., Mao H.Q., Leong K.W. Polyphosphoesters in drug and gene delivery. Adv. Drug Deliv. Rev. 2003, 55:483-499.
226. Mao H.Q., Leong K.W. Design of polyphosphoester-DNA nanoparticles for non-viral gene delivery. Adv. Genet. 2005, 53:275-306.
227. Wang J., Zhang P.C., Mao H.Q., Leong K.W. Enhanced gene expression in mouse muscle by sustained release of plasmid DNA using PPE-EA as a carrier. Gene Ther. 2002, 9:1254-1261.
228. Sun T.M., Du J.Z., Yan L.F., Mao H.Q., Wang J. Self-assembled biodegradable micellar nanoparticles of amphiphilic and cationic block copolymer for siRNA delivery. Biomaterials 2008, 29:4348-4355.
229. DeRouchey J., Schmidt C., Walker G.F., Koch C., Plank C., Wagner E., Radler J.O. Monomolecular assembly of siRNA and poly(ethylene glycol)-peptide copolymers. Biomacromolecules 2008, 9:724-732.
230. Shim M.S., Kwon Y.J. Controlled delivery of plasmid DNA and siRNA to intracellular targets using ketalized polyethylenimine. Biomacromolecules 2008, 9:444-455.
231. Soutschek J., Akinc A., Bramlage B., Charisse K., Constien R., Donoghue M., Elbashir S., Geick A., Hadwiger P., Harborth J., John M., Kesavan V., Lavine G., Pandey R.K., Racie T., Rajeev K.G., Rohl I., Toudjarska I., Wang G., Wuschko S., Bumcrot D., Koteliansky V., Limmer S., Manoharan M., Vornlocher H.P. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004, 432:173-178.
232. Wolfrum C., Shi S., Jayaprakash K.N., Jayaraman M., Wang G., Pandey R.K., Rajeev K.G., Nakayama T., Charrise K., Ndungo E.M., Zimmermann T., Koteliansky V., Manoharan M., Stoffel M. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat. Biotechnol. 2007, 25:1149-1157.
233. Lorenz C., Hadwiger P., John M., Vornlocher H.P., Unverzagt C. Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg. Med. Chem. Lett. 2004, 14:4975-4977.
234. Nishina K., Unno T., Uno Y., Kubodera T., Kanouchi T., Mizusawa H., Yokota T. Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol. Mol. Ther. 2008, 16:734-740.
235. Chiu Y.L., Ali A., Chu C.Y., Cao H., Rana T.M. Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem. Biol. 2004, 11:1165-1175.
236. Moschos S.A., Jones S.W., Perry M.M., Williams A.E., Erjefalt J.S., Turner J.J., Barnes P.J., Sproat B.S., Gait M.J., Lindsay M.A. Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug. Chem. 2007, 18:1450-1459.
237. Muratovska A., Eccles M.R. Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett. 2004, 558:63-68.
238. Lee S.H., Kim S.H., Park T.G. Intracellular siRNA delivery system using polyelectrolyte complex micelles prepared from VEGF siRNA-PEG conjugate and cationic fusogenic peptide. Biochem. Biophys. Res. Commun. 2007, 357:511-516.
239. Kim S.H., Jeong J.H., Lee S.H., Kim S.W., Park T.G. PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J. Control. Release 2006, 116:123-129.
240. Kim S.H., Jeong J.H., Lee S.H., Kim S.W., Park T.G. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J. Control. Release 2008, 129:107-116.
241. Oishi M., Nagasaki Y., Itaka K., Nishiyama N., Kataoka K. Lactosylated poly(ethylene glycol)-siRNA conjugate through acid-labile beta-thiopropionate linkage to construct pH-sensitive polyion complex micelles achieving enhanced gene silencing in hepatoma cells. J. Am. Chem. Soc. 2005, 127:1624-1625.
242. Oishi M., Nagasaki Y., Nishiyama N., Itaka K., Takagi M., Shimamoto A., Furuichi Y., Kataoka K. Enhanced growth inhibition of hepatic multicellular tumor spheroids by lactosylated poly(ethylene glycol)-siRNA conjugate formulated in PEGylated polyplexes. ChemMedChem 2007, 2:1290-1297.
243. Medarova Z., Kumar M., Ng S.W., Yang J., Barteneva N., Evgenov N.V., Petkova V., Moore A. Multifunctional magnetic nanocarriers for image-tagged SiRNA delivery to intact pancreatic islets. Transplantation 2008, 86:1170-1177.
244. Narang A.S., Sabek O., Gaber A.O., Mahato R.I. Co-expression of vascular endothelial growth factor and interleukin-1 receptor antagonist improves human islet survival and function. Pharm. Res. 2006, 23:1970-1982.
245. Bain J.R., Schisler J.C., Takeuchi K., Newgard C.B., Becker T.C. An adenovirus vector for efficient RNA interference-mediated suppression of target genes in insulinoma cells and pancreatic islets of langerhans. Diabetes 2004, 53:2190-2194.
246. Iezzi M., Eliasson L., Fukuda M., Wollheim C.B. Adenovirus-mediated silencing of synaptotagmin 9 inhibits Ca2+-dependent insulin secretion in islets. FEBS Lett. 2005, 579:5241-5246.
247. Jensen M.V., Joseph J.W., Ilkayeva O., Burgess S., Lu D., Ronnebaum S.M., Odegaard M., Becker T.C., Sherry A.D., Newgard C.B. Compensatory responses to pyruvate carboxylase suppression in islet beta-cells. Preservation of glucose-stimulated insulin secretion. J. Biol. Chem. 2006, 281:22342-22351.
248. Li Z.L., Xu W.J., Tian P.X., Ding X.M., Tian X.H., Feng X.S., Hou J. Recombinant adenovirus-mediated RNA silencing of tissue factor expression in human islet: an in vitro study. Nan Fang Yi Ke Da Xue Xue Bao 2007, 27:1299-1302.
249. Marzban L., Tomas A., Becker T.C., Rosenberg L., Oberholzer J., Fraser P.E., Halban P.A., Verchere C.B. Small interfering RNA-mediated suppression of proislet amyloid polypeptide expression inhibits islet amyloid formation and enhances survival of human islets in culture. Diabetes 2008, 57:3045-3055.
250. Naldini L. Lentiviruses as gene transfer agents for delivery to non-dividing cells. Curr. Opin. Biotechnol. 1998, 9:457-463.
251. Burns J.C., Friedmann T., Driever W., Burrascano M., Yee J.K. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl Acad. Sci. USA 1993, 90:8033-8037.
252. Kobinger G.P., Deng S., Louboutin J.P., Vatamaniuk M., Matschinsky F., Markmann J.F., Raper S.E., Wilson J.M. Transduction of human islets with pseudotyped lentiviral vectors. Hum. Gene Ther. 2004, 15:211-219.
253. Fenjves E.S., Ochoa M.S., Cechin S., Gay-Rabinstein C., Perez-Alvarez I., Ichii H., Mendez A., Ricordi C., Curran M.A. Protection of human pancreatic islets using a lentiviral vector expressing two genes: cFLIP and GFP. Cell Transplant. 2008, 17:793-802.
254. Lu Y., Dang H., Middleton B., Zhang Z., Washburn L., Campbell-Thompson M., Atkinson M.A., Gambhir S.S., Tian J., Kaufman D.L. Bioluminescent monitoring of islet graft survival after transplantation. Mol. Ther. 2004, 9:428-435.
255. Park I.K., Lasiene J., Chou S.H., Horner P.J., Pun S.H. Neuron-specific delivery of nucleic acids mediated by Tet1-modified poly(ethylenimine). J. Gene Med. 2007, 9:691-702.
256. Fernandes J.R., Duvivier-Kali V.F., Keegan M., Hollister-Lock J., Omer A., Su S., Bonner-Weir S., Feng S., Lee J.S., Mulligan R.C., Weir G.C. Transplantation of islets transduced with CTLA4-Ig and TGFbeta using adenovirus and lentivirus vectors. Transpl. Immunol. 2004, 13:191-200.
257. Giannoukakis N., Mi Z., Gambotto A., Eramo A., Ricordi C., Trucco M., Robbins P. Infection of intact human islets by a lentiviral vector. Gene Ther. 1999, 6:1545-1551.
258. Gallichan W.S., Kafri T., Krahl T., Verma I.M., Sarvetnick N. Lentivirus-mediated transduction of islet grafts with interleukin 4 results in sustained gene expression and protection from insulitis. Hum. Gene Ther. 1998, 9:2717-2726.
259. He Z., Wang F., Kumagai-Braesch M., Permert J., Holgersson J. Long-term gene expression and metabolic control exerted by lentivirus-transduced pancreatic islets. Xenotransplantation 2006, 13:195-203.
260. Callewaert H., Gysemans C., Cardozo A.K., Elsner M., Tiedge M., Eizirik D.L., Mathieu C. Cell loss during pseudoislet formation hampers profound improvements in islet lentiviral transduction efficacy for transplantation purposes. Cell Transplant. 2007, 16:527-537.
261. Barbu A.R., Bodin B., Welsh M., Jansson L., Welsh N. A perfusion protocol for highly efficient transduction of intact pancreatic islets of Langerhans. Diabetologia 2006, 49:2388-2391.
262. Kim S.S., Ye C., Kumar P., Chiu I., Subramanya S., Wu H., Shankar P., Manjunath N. Targeted delivery of siRNA to macrophages for anti-inflammatory treatment. Mol. Ther. 2010, 18:993-1001.
263. Macedo G.C., Magnani D.M., Carvalho N.B., Bruna-Romero O., Gazzinelli R.T., Oliveira S.C. Central role of MyD88-dependent dendritic cell maturation and proinflammatory cytokine production to control Brucella abortus infection. J. Immunol. 2008, 180:1080-1087.